Replies to post #893 on Israel-Medical-Healthcare

[genisi]

They check more autoimmune diseases as candidates for CF101 especially now after finding a marker in the blood. That might be the parachute they need to stop them from free falling, in case the RA phase II trial blows up.

[midastouch017]

FDA approves Phase I trial for Can-Fite cancer drug
The trial is due to begin at the start of the first quarter of 2008.
Shira Horesh 7 Jan 08 14:20
Can-Fite BioPharma Ltd. (TASE:CFBI) has obtained US Food and Drug Administration (FDA) approval to conduct Phase I human clinical trials for the company's cancer treatment CF102. This is the company's second drug in its development pipeline.
Can-Fite currently intends to develop CF102 to treat liver cancer and other liver diseases. The market for liver cancer treatments is estimated at $500 million. The company notes that liver cancer is prevalent among patients with hepatitis and among alcoholics, and that the disease is common in the Far East, where it is the number one cause of mortality for cancer. 630,000 new cases of liver cancer are diagnosed annually.


CF102 has been shown to be effective against liver cancer in laboratory testing and in preclinical trials. The preclinical trials showed the drug to have the maximum safety profile, a precondition for moving on to human clinical trials.

The Phase I clinical trial will be conducted by a suitable research company on healthy volunteers in the US. The trial will indicate whether CF102 is safe for human use, and if so, will enable Can-Fite to proceed to Phase II trials on patients with liver cancer. The Phase I trial is due to begin at the start of the first quarter of 2008 and the results are due towards the end of the quarter.

Published by Globes [online], Israel business news - www.globes-online.com - on January 7, 2008